Home>Topics>Stocks>Alnylam Pharmaceuticals

Alnylam Pharmaceuticals ALNY

  1. All
  2. Commentary
  3. Stock Reports
  4. ETF Reports
  5. Headlines
    1. Alnylam receives NOA for RNAi-mediating molecules

      Headlines

      Wed, 20 Aug 2014

      The USPTO issues a Notice of Allowance to Alnylam Pharmaceuticals ( ALNY -0.5% ) for claims in the Tuschl et al. patent application 13/725,262. The 262 patent application includes claims directed

    2. Alnylam Pharmaceuticals Has Plenty On Its Plate

      Headlines

      Sat, 9 Aug 2014

      sector since the spring of this year, leading to unimpressive performance for leading RNAi companies Alnylam Pharmaceuticals (NASDAQ: ALNY ) and Isis Pharmaceuticals (NASDAQ: ISIS ). I won't try to argue that valuations didn't get overheated

    3. Alnylam's 2Q as Expected; Pipeline Progress Continues

      Commentary

      Fri, 8 Aug 2014

      Alnylam Pharmaceuticals reported second-quarter results that were largely consistent with our expectations, and we're maintaining our $66 fair value

    4. New Morningstar Analyst Report for Alnylam Pharmaceuticals Inc

      Stock Reports

      Fri, 8 Aug 2014

      of options issued as a percentage of shares outstanding, putting shareholders at risk for future dilution. Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class

    5. Alnylam Pharmaceuticals' ( ALNY ) CEO John Maraganore on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 7 Aug 2014

      Alnylam Pharmaceuticals , Inc. (NASDAQ: ALNY ) Q2 2014 Earnings Conference Call August 7, 2014 5:00 ..... Operator Good day ladies and gentlemen and welcome to the Alnylam Pharmaceuticals ’ Q2 2014 Earnings Conference Call. At this time all

    6. More on Alnylam Q2 results

      Headlines

      Thu, 7 Aug 2014

      Alnylam Pharmaceuticals ( ALNY -2% ) Q2 results : Collaboration Revenue: $7.3M (-16.0%); Operating Loss: ($45.0M) (-111.3%); Net Loss

    7. Alnylam Pharmaceuticals ( ALNY ) Q2 2014 Results - Earnings Call Webcast

      Headlines

      Thu, 7 Aug 2014

      The following audio is from a conference call that will begin on August 07, 2014 at 16:30 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »

    8. Alnylam Pharmaceuticals misses by $0.08, misses on revenue

      Headlines

      Thu, 7 Aug 2014

      Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q2 EPS of -$0.63 misses by $0.08 . Revenue of $7.3M (-16.0% Y/Y) misses by $2.06M . Shares +1.3% . Press Release Post your comment!

    9. EMA designates ALN-AT3 an orphan drug

      Headlines

      Thu, 7 Aug 2014

      The EMA's Committee for Orphan Medicinal Products designates Alnylam's (NASDAQ: ALNY ) ALN-AT3 an orphan drug for the treatment of hemophilia A and hemopholia B. ALN-AT3 is an RNA therapeutic that targets antithrombin . Post your comment!

    10. Christopher James Turns A Clinical Eye On Biotechs With High Reward Potential

      Headlines

      Mon, 4 Aug 2014

      By Life Sciences Report : A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand, recommends that investors willing to diversify their holdings and take on informed

    « Prev1234Next »
    Content Partners